We are live on ! Find out more
KROS icon

Keros Therapeutics
KROS

161 hedge funds and large institutions have $582M invested in Keros Therapeutics in 2024 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 30 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

147% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 30

3% less call options, than puts

Call options by funds: $10.8M | Put options by funds: $11.2M

5% less first-time investments, than exits

New positions opened: 38 | Existing positions closed: 40

1% less funds holding

Funds holding: 163 → 161 (-2)

2.39% less ownership

Funds ownership: 93.1% → 90.72% (-2.4%)

60% less funds holding in top 10

Funds holding in top 10: 5 → 2 (-3)

71% less capital invested

Capital invested by funds: $2.03B → $582M (-$1.45B)

Holders
161
Holders Change
-2
Holders Change %
-1.23%
% of All Funds
2.12%
Holding in Top 10
2
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-60%
% of All Funds
0.03%
New
38
Increased
74
Reduced
30
Closed
40
Calls
$10.8M
Puts
$11.2M
Net Calls
-$380K
Net Calls Change
-$4.32M

Top Buyers

1
B
Braidwell
Connecticut
+$61.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$33.5M
3
LCM
Lynx1 Capital Management
Puerto Rico
+$28.3M
4
NCM
Nantahala Capital Management
Connecticut
+$27.7M
5
MP
Mangrove Partners
Connecticut
+$23.4M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$49.2M
2
Alkeon Capital Management
Alkeon Capital Management
New York
-$41.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$31.4M
4
PBA
Paradigm Biocapital Advisors
New York
-$30.5M
5
OM
Opaleye Management
Massachusetts
-$23M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$87.8M +$33.5M +644,174 +13%
BlackRock
2
BlackRock
New York
$43.2M +$5.02M +96,670 +4%
Vanguard Group
3
Vanguard Group
Pennsylvania
$31M +$5.23M +100,691 +5%
B
4
Braidwell
Connecticut
$30M +$61.7M +1,187,199 +168%
DGM
5
Darwin Global Management
Jersey
$26.7M +$8.49M +163,403 +11%
State Street
6
State Street
Massachusetts
$19M +$4.67M +89,793 +8%
Holocene Advisors
7
Holocene Advisors
New York
$19M +$18.5M +356,880 +42%
Alkeon Capital Management
8
Alkeon Capital Management
New York
$17.4M -$41.4M -796,601 -42%
O
9
OrbiMed
New York
$16.1M – – –
NCM
10
Nantahala Capital Management
Connecticut
$14.5M +$27.7M +533,389 +140%
T. Rowe Price Associates
11
T. Rowe Price Associates
Maryland
$14.4M -$31.4M -604,798 -40%
Millennium Management
12
Millennium Management
New York
$13.9M +$15.9M +305,169 +53%
JFG
13
Jefferies Financial Group
New York
$13.7M – – –
Citadel Advisors
14
Citadel Advisors
Florida
$12.5M +$4.48M +86,186 +12%
Geode Capital Management
15
Geode Capital Management
Massachusetts
$12.1M +$2.07M +39,815 +5%
MP
16
Mangrove Partners
Connecticut
$11.7M +$23.4M +449,390 +157%
Morgan Stanley
17
Morgan Stanley
New York
$10.4M +$15.1M +291,504 +80%
RG
18
Redmile Group
California
$8.75M – – –
TCM
19
TCG Crossover Management
California
$8.71M -$17.1M -329,344 -37%
LCM
20
Lynx1 Capital Management
Puerto Rico
$8.61M +$28.3M +544,001 New
Goldman Sachs
21
Goldman Sachs
New York
$8.48M +$9.35M +179,920 +51%
IHAM
22
Integral Health Asset Management
New York
$7.12M +$13M +250,000 +125%
CCM
23
Catalio Capital Management
New York
$6.45M +$21.2M +407,292 New
WP
24
Woodline Partners
California
$6.14M -$19.5M -375,847 -49%
EAM
25
Eventide Asset Management
Massachusetts
$6.02M – – –
1
2 3 4 5

KROS Hedge Fund Activity: Q4 2024 in Review

161 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2024, worth a combined $582M — down 71% from $2.03B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of KROS and 38 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 74 added.

The largest buyer was Braidwell, adding an estimated $61.7M. The largest seller was Point72 Asset Management, cutting an estimated $49.2M.

  • 161 institutional investors held Keros Therapeutics (KROS) as of Q4 2024, down from 163 in Q3 2024.
  • Funds reported $582M of Keros Therapeutics stock for Q4 2024, down 71% quarter-over-quarter.
  • 38 funds opened new Keros Therapeutics positions in Q4 2024 and 40 closed out, a net change of -2 holders.
  • The largest Keros Therapeutics buyer in Q4 2024 was Braidwell, an estimated $61.7M added.
  • The largest Keros Therapeutics seller in Q4 2024 was Point72 Asset Management, an estimated $49.2M sold.

Based on aggregated 13F filings for Q4 2024.